Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
7.82
-0.30 (-3.69%)
May 13, 2025, 4:00 PM - Market closed
Aurinia Pharmaceuticals Revenue
Aurinia Pharmaceuticals had revenue of $62.47M in the quarter ending March 31, 2025, with 24.18% growth. This brings the company's revenue in the last twelve months to $247.30M, up 29.20% year-over-year. In the year 2024, Aurinia Pharmaceuticals had annual revenue of $235.13M with 33.97% growth.
Revenue (ttm)
$247.30M
Revenue Growth
+29.20%
P/S Ratio
4.48
Revenue / Employee
$1,902,269
Employees
130
Market Cap
1.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 235.13M | 59.62M | 33.97% |
Dec 31, 2023 | 175.51M | 41.48M | 30.95% |
Dec 31, 2022 | 134.03M | 88.43M | 193.89% |
Dec 31, 2021 | 45.61M | -4.51M | -9.00% |
Dec 31, 2020 | 50.12M | 49.80M | 15,660.38% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AUPH News
- 1 day ago - Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga
- 1 day ago - Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 - Business Wire
- 9 days ago - Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 - Business Wire
- 14 days ago - Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - Business Wire
- 15 days ago - ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting - Business Wire
- 17 days ago - Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth - Seeking Alpha
- 20 days ago - Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting - Business Wire